What the FDA labels say about taking them together
Amitriptyline and risperidone
Risperidone's FDA label of May 28, 2026 names amitriptyline in its drug interactions section; the amitriptyline label PlainMeds reads does not name risperidone. The risperidone label: “Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).”
Check it at the source: the amitriptyline FDA label on DailyMed (effective September 8, 2026, Sun Pharmaceutical Industries, Inc.); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the amitriptyline label say about risperidone?
Amitriptyline's label (effective September 8, 2026) does not name risperidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Amitriptyline Hydrochloride), Sun Pharmaceutical Industries, Inc., effective September 8, 2026 (SPL set 4e520c63-1cf6-40f6-a51c-3f9b0e181342), via openFDA; the full label on DailyMed
What does the risperidone label say about amitriptyline?
Risperidone label, drug interactionsDose adjustment is not recommended for RISPERDAL when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin [see Table 18 ].
Risperdal Consta label (Janssen Pharmaceuticals, Inc., November 5, 2025), drug interactionsAmitriptyline did not affect the pharmacokinetics of risperidone or of risperidone and 9-hydroxyrisperidone combined following concomitant administration with oral RISPERDAL.
Rykindo Extended-Release Microspheres label (Shandong Luye Pharmaceutical Co., Ltd., May 26, 2026), drug interactionsClinical Impact: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). … with oral risperidone, no dosage adjustment of RYKINDO ® is required when administered concomitantly with amitriptyline, cimetidine, ranitidine, clozapine, topiramate and moderate CYP3A4 inhibitors (erythromycin). …
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (Risperidone, NDA020588), Janssen Pharmaceuticals, Inc., effective August 20, 2026 (SPL set 701e1cd8-2868-4d29-85a9-a2212c88165f), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amitriptyline | Risperidone | |
|---|---|---|
| Labeled for | Depression | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.03 per tablet 10 mg tablet | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once